Pediatric exclusivity
This article was originally published in The Tan Sheet
Executive Summary
Generic associations file for injunction to stop further FDA implementation of the FDA Modernization Act's pediatric exclusivity provisions. The Generic Pharmaceutical Industry Association and the National Pharmaceutical Alliance argue in the suit, filed in D.C. federal court, that the agency's pediatric policy caters to interests of innovator companies rather than serving interests of children by extending exclusivity protections to products that, in some cases, are not even used in children. The associations cite the pediatric exclusivity award for Glaxo Wellcome's Zantac 75, marketed OTC by Warner-Lambert, as an example
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning